Saama Makes Analytics Platform Available to Organizations Investigating COVID-19 Treatments
Saama Technologies (Campbell, CA) has announced that it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium. The single goal, the company reports, is “to integrate data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50%.” Saama’s platform will allow researchers to dynamically visualize, analyze, and interrogate data across all available programs.
Suresh Katta, Founder and CEO of Saama Technologies, commented: “We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatments - and hopefully a cure - for SARS-CoV-2.”
David Shulkin, M.D., the Ninth Secretary, US Department of Veterans Affairs, added: “We won’t find rapid solutions for the SARS-CoV-2 pandemic with our data remaining so fragmented. In order to adequately address [it], we must share data from clinical studies across the research, healthcare, and pharma communities.”
Companies interested in joining the EndPandemic National Data Consortium to collaborate and accelerate solutions to the pandemic should contact Saama at endpandemic@saama.com or call 888.970.3550.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
